
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Approvals· August 12, 2026 · 34 min read
By Ran Chen#FDA Approval#HIV#Gilead Sciences

Approvals· August 12, 2026 · 39 min read
MK-6240 (Florquinitau F-18) Tau PET: PDUFA, Tauvid, and CMS Coverage Gap
By Ran Chen#FDA Approval#PDUFA Date#Medicare

Pipeline· August 11, 2026 · 14 min read
Ivonescimab: the PD-1/VEGF Bispecific Ahead of Nov 2026 FDA Action
By Ran Chen#FDA Approval#Oncology#Bispecific Antibody

Approvals· August 11, 2026 · 20 min read
Orzeyful (Oveporexton): the First Orexin-2 Agonist, FDA-Approved for Narcolepsy Type 1

Approvals· August 10, 2026 · 14 min read
177Lu-Edotreotide (ITM-11) for GEP-NET: COMPETE Phase 3 Data and Lutathera Access
By Ran Chen#Radiolabeled Therapy#Oncology#FDA Approval

Specialty· August 10, 2026 · 19 min read
Dermatomyositis Treatment Access (2026): Brepocitinib, Octagam IVIG, and DMARDs

Specialty· August 9, 2026 · 20 min read
Aesthetic Procedure Adverse Events by the Numbers (2026)

Manufacturing· August 7, 2026 · 18 min read
AI Dossier Governance Checklist: What DJ Fang's Benchmark Means for eCTD Teams
By Ran Chen#FDA Approval#Policy#Manufacturing

Approvals· August 7, 2026 · 14 min read
Iberdomide FDA PDUFA review: first-in-class CELMoD for multiple myeloma
By Ran Chen#FDA Approval#Multiple Myeloma#Oncology

Deals· August 6, 2026 · 13 min read
Gilead's $7.8B Arcellx Acquisition: Anito-Cel Deal Anatomy
By Ran Chen#Gilead Sciences#Arcellx#anito-cel